newsfilter
← Latest News
PR Newswire·

Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

  • Protalix BioTherapeutics, Inc. will release fiscal year 2025 financial results & provide a business update on March 18, 2026.
  • Management will host a conference call at 8:00 a.m. EDT to discuss results & recent corporate/regulatory developments.
  • Conference call access includes toll-free, international, & Israeli toll-free numbers, with a Call me™ feature available at http://bit.ly/4aOQNnE.
  • The event will be webcast live via the company's investor relations website, with a specific link provided for access.
  • Participants are requested to join 15 minutes early, & a call replay will be available for two weeks on the company website.
  • Protalix utilizes the ProCellEx plant cell-based expression system & holds FDA approval for taliglucerase alfa & Elfabrio.
  • Taliglucerase alfa is licensed to Pfizer globally, excluding Brazil, where Protalix retains rights.
  • Elfabrio is being developed & commercialized globally in partnership with Chiesi Farmaceutici S.p.A.
  • The development pipeline includes PRX–115 for uncontrolled gout & PRX–119 for NETs-related diseases.
  • Investor inquiries can be directed to Mike Moyer at LifeSci Advisors.